HUMANIZED ANTIBODY AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4

• Main Authors: BENDIG MARY M, SALDANHA JOSE, JONES S TARRAN, LEGER OLIVIER J
• Format: Patent
• Language: English
• Published: 05.09.2013
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; DERIVATIVES THEREOF; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; NUCLEIC ACIDS; NUCLEOSIDES; NUCLEOTIDES; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES USING MICROORGANISMS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; SUGARS; TESTING; VINEGAR; WINE

PROBLEM TO BE SOLVED: To provide a humanized antibody having no immunogenicity while exhibiting a strong binding affinity to a VLA-4 receptor.SOLUTION: A humanized immunoglobulin includes a humanized light chain comprising three complementarity-determining regions having amino acid sequences from the corresponding complementarity-determining regions of the mouse 21.6 immunoglobulin light chain variable domain, and a variable region framework from a human kappa light chain variable region framework sequence, provided that at least one position selected from a first group consisting of L45, L49, L58 and L69 (Kabat numbering convention) is occupied by the same amino acid residue present in the equivalent position of the mouse 21.6 immunoglobulin light chain variable region framework.